Trevi Therapeutics, Inc. (TRVI) Stock Price & Analysis
Trevi Therapeutics, Inc. (TRVI) closed at USD 12.94 on Thursday, October 22, 2026, up 1.33% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.94; the Oct 22, 2026 session ranged USD 12.53–13.22 on volume of 1,184,809 shares. Market capitalization is —, with a 52-week range of USD 9.82–20.22 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TRVI.md
Key facts (TRVI)
- 1 of 80 tracked superinvestors hold TRVI (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +21.5% vs S&P 500 +14.9%; 5Y +960.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.13, revenue estimate $0K.
Superinvestors (SEC 13F-HR, Q2 2026) (TRVI)
1 of 80 tracked investors hold TRVI. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.08% | $28.8M | Reduced -51.7% |
Analysts (TRVI)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Jones Trading | Target raised | Buy | $24 → $28 |
| 2026-08-07 | Oppenheimer | Target raised | Outperform | $24 → $25 |
| 2026-08-07 | Cantor Fitzgerald | Target raised | Overweight | $25 → $30 |
| 2026-07-21 | BMO Capital | Initiated | Outperform | $36 |
| 2026-07-20 | B. Riley Securities | Target raised | Buy | $21 → $31 |
| 2026-07-20 | HC Wainwright & Co. | Target raised | Buy | $21 → $24 |
Total return (dividends reinvested) (TRVI)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +21.5% | +960.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +21.6% | +60.2% |
| Volatility (annualized) | 57.5% | 93.2% |
| Max drawdown | -39.1% (Jul 2026→Oct 2026) | -73.0% (Aug 2022→Nov 2023) |
TRVI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.13 | +3.1% | $0 | 10 |
| Next quarter (ends Dec 2026) | $-0.14 | $-0.14 | +3.6% | $0 | 10 |
| Current fiscal year (ends Dec 2026) | $-0.48 | $-0.46 | +3.2% | $0 | 10 |
| Next fiscal year (ends Dec 2027) | $-0.58 | $-0.56 | +3.4% | $0 | 10 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 12.94 |
|---|---|
| Change | ▲ 1.33% (up) |
| Previous Close | USD 12.94 |
| Open | USD 12.94 |
| Day Range | USD 12.53 – 13.22 |
| 52-Week Range | USD 9.82 – 20.22 |
| Volume | 1,184,809 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (TRVI)
Nexqual's technical model rates TRVI "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.69 (neutral) |
| vs SMA50 | Below (USD 15.32) |
| MACD | -0.8 (negative) |
Earnings (TRVI)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.1 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (TRVI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -19.66% |
| Debt / Equity | 0 |
| Current Ratio | 37.28 |
| Total Cash | $318.87M |
| Total Debt | $605,000 |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (TRVI)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +109.72% |
| Shares Outstanding | 142.48M |
| Float | 118.32M |
| Short % of Float | +11.41% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | USD 3.68 | ▼ 0.54% |
| XFOR | X4 Pharmaceuticals, Inc. | USD 3.2 | ▲ 6.31% |
| STOK | Stoke Therapeutics, Inc. | USD 25.7 | ▲ 0.08% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 3.83 | ▲ 5.51% |
| TARA | Protara Therapeutics, Inc. | USD 2.44 | ▼ 2.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt